|
|
Volumn 32, Issue 12, 2014, Pages 1171-1172
|
|
Developers seek to finetune toxicity of T-cell therapies
a
a
NONE
(United States)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CHIMERIC ANTIGEN RECEPTOR;
GAMMA INTERFERON;
INTERLEUKIN 6;
RIMIDUCID;
RITUXIMAB;
T LYMPHOCYTE RECEPTOR;
TISAGENLECLEUCEL T;
TOCILIZUMAB;
CD19 ANTIGEN;
LYMPHOCYTE ANTIGEN RECEPTOR;
ACUTE LYMPHOBLASTIC LEUKEMIA;
APOPTOSIS;
BONE MARROW TRANSPLANTATION;
CANCER IMMUNOTHERAPY;
CHILDHOOD CANCER;
CHRONIC LYMPHATIC LEUKEMIA;
CYTOKINE RELEASE;
CYTOKINE RELEASE SYNDROME;
CYTOKINE STORM;
DRUG INDUCED DISEASE;
DRUG SAFETY;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LEUKEMIA REMISSION;
NATIONAL HEALTH ORGANIZATION;
NEUROBLASTOMA;
NOTE;
OSTEOSARCOMA;
OVARY CANCER;
PATIENT CARE;
PERSONAL EXPERIENCE;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
RHEUMATOID ARTHRITIS;
SYNOVIAL SARCOMA;
T CELL THERAPY;
T LYMPHOCYTE;
TUMOR VOLUME;
ADOPTIVE IMMUNOTHERAPY;
ADVERSE DRUG REACTION;
GENETICS;
IMMUNOLOGY;
PATHOLOGY;
PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;
ANTIGENS, CD19;
DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS;
HUMANS;
IMMUNOTHERAPY, ADOPTIVE;
PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;
RECEPTORS, ANTIGEN, T-CELL;
|
|
EID: 84924413387
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt1214-1171 Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|
